Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Qualified Opinion who wrote (3572)	11/15/2002 9:57:18 PM
From: Cacaito	Respond to of 10345

..."with antibodies against amyloid, rather than amyloid itself."... These researchers used antibodies, not the whole amyloid vaccine, nor a portion of it. It is just one of the approaches and not the whole amyloid vaccine used by Elan in the halted vaccine program. There are not reported bleedings cause by the vaccine in the Elan whole vaccine program. Even the antibodies approach could be variable, directed to different segments of the amyloid protein and/or different manufacturing, monoclonals vs plasma derived, and kinetics. Lipitor has been shown in animals that they could fight the vasculitis in Alzheimer, a combo could do the trick. Of course, most of the post is speculation. Very tricky, use the vaccine and get meningitis, use the antibodies and get bleeding from weak vessels !!!